Literature DB >> 19692269

IL-17 inhibits human Th1 differentiation through IL-12R beta 2 downregulation.

Myew-Ling Toh1, Masanori Kawashima, Saloua Zrioual, Arnaud Hot, Philippe Miossec, Pierre Miossec.   

Abstract

Th17 cells are critical in adaptive immunity and autoimmune disease. The polarized development of Th17, Th1 and Th2 cells is dependent on counterregulatory effects on each other. Whereas IFN-gamma inhibits Th17 development, the effect of IL-17 in human Th1 development is not known. We report a novel negative regulatory role of IL-17 on IL-12R beta 2 expression associated with reduced IL-12 responsiveness. IL-17 decreased IL-12-induced IFN-gamma expression in PBMC and developing Th1 cells, associated with a selective reduction in IL-12R beta 2, and not IL-23R, IL-12R beta 1 or T-bet. Counterregulatory effects of human Th17 on Th1 lineage cytokines may contribute to lineage divergence. In autoimmune disease, IL-17 may reinforce its own developmental programme by reducing IL-12 responsiveness, thus limiting inhibitory effects of IFN-gamma on Th17 development.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19692269     DOI: 10.1016/j.cyto.2009.07.013

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  14 in total

1.  Human leukocyte antigen-G expression on dendritic cells induced by transforming growth factor-beta1 and CD4+ T cells proliferation.

Authors:  Saeid Abediankenari; Maryam Ghasemi; Young-June Kim
Journal:  Iran Biomed J       Date:  2011

2.  Interleukin-17A promotes early but attenuates established disease in crescentic glomerulonephritis in mice.

Authors:  Dragana Odobasic; Poh-Yi Gan; Shaun A Summers; Tim J Semple; Ruth C M Muljadi; Yoichiro Iwakura; A Richard Kitching; Stephen R Holdsworth
Journal:  Am J Pathol       Date:  2011-07-08       Impact factor: 4.307

3.  Substance P enhances Th17 phenotype in individuals with generalized anxiety disorder: an event resistant to glucocorticoid inhibition.

Authors:  Priscila O Barros; Thais B Ferreira; Morgana M M Vieira; Carla Renata M Almeida; Carlos Fernando Araújo-Lima; Renato G Silva-Filho; Joana Hygino; Regis M Andrade; Arnaldo F Andrade; Cleonice A Bento
Journal:  J Clin Immunol       Date:  2010-09-24       Impact factor: 8.317

4.  Interleukin-17A during local and systemic Staphylococcus aureus-induced arthritis in mice.

Authors:  Louise Henningsson; Pernilla Jirholt; Catharina Lindholm; Tove Eneljung; Elin Silverpil; Yoichiro Iwakura; Anders Linden; Inger Gjertsson
Journal:  Infect Immun       Date:  2010-06-28       Impact factor: 3.441

Review 5.  Interleukin-17 in inflammatory myopathies.

Authors:  Anne Tournadre; Pierre Miossec
Journal:  Curr Rheumatol Rep       Date:  2012-06       Impact factor: 4.592

6.  IFN-γ protects from lethal IL-17 mediated viral encephalomyelitis independent of neutrophils.

Authors:  Carine Savarin; Stephen A Stohlman; David R Hinton; Richard M Ransohoff; Daniel J Cua; Cornelia C Bergmann
Journal:  J Neuroinflammation       Date:  2012-05-29       Impact factor: 8.322

7.  Prevalence, distribution and functional significance of the -237C to T polymorphism in the IL-12Rβ2 promoter in Indian tuberculosis patients.

Authors:  Vikas Kumar Verma; Vibha Taneja; Anand Jaiswal; Sangeeta Sharma; Digamber Behera; Vishnubhatla Sreenivas; Shyam Singh Chauhan; Hanumanthappa Krishna Prasad
Journal:  PLoS One       Date:  2012-04-03       Impact factor: 3.240

8.  Marking and quantifying IL-17A-producing cells in vivo.

Authors:  April E Price; R Lee Reinhardt; Hong-Erh Liang; Richard M Locksley
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

Review 9.  Reactivation of latent tuberculosis with TNF inhibitors: critical role of the beta 2 chain of the IL-12 receptor.

Authors:  Marie Robert; Pierre Miossec
Journal:  Cell Mol Immunol       Date:  2021-05-21       Impact factor: 22.096

10.  IL-17A and IL-2-expanded regulatory T cells cooperate to inhibit Th1-mediated rejection of MHC II disparate skin grafts.

Authors:  Benoît Vokaer; Louis-Marie Charbonnier; Philippe H Lemaître; Chloé Spilleboudt; Alain Le Moine
Journal:  PLoS One       Date:  2013-10-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.